In reply

Anesthesiology

Volumn 117, Issue 4, 2012, Pages 921-922

  Karkouti, Keyvan ^a   Wijeysundera, Duminda N ^b   Yau, Terrence M ^b   McCluskey, Stuart A ^b   Chan, Christopher T ^b   Crowther, Mark A ^b   Beattie, W Scott ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ERYTHROPOIETIN STIMULATING AGENT; HEMATOLOGIC AGENT; HEMOGLOBIN; UNCLASSIFIED DRUG;

ANEMIA; CARDIOPULMONARY BYPASS; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FATALITY; HEART SURGERY; HEMODILUTION; HUMAN; INTERVENTION STUDY; LETTER; OFF PUMP SURGERY; PRIORITY JOURNAL; SURGICAL PATIENT; SURGICAL RISK;

EID: 84866706519     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182690d90     Document Type: Letter

References (13)

1. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wong PY, Crowther MA, Hozhabri S, Beattie WS: Advance targeted transfusion in anemic cardiac surgical patients for kidney protection: An unblinded randomized pilot clinical trial. ANESTHESIOLOGY 2012; 116:613-21
2. Meinert CL: Clinical Trials: Design, Conduct, and Analysis, 2nd edition. New York, Oxford University Press, 2012
3. Carson JL, Noveck H, Berlin JA, Gould SA: Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812-8
4. Vamvakas EC, Blajchman MA: Blood still kills: Six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24:77-124
5. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H, SHOT Steering Group: Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev 2006; 20:273-82 (Pubitemid 44428107)
6. Cohen JT, Neumann PJ: What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Aff (Millwood) 2007; 26:636-46
7. Marik PE, Corwin HL: Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature. Crit Care Med 2008; 36:2667-74
8. Bennett-Guerrero E, Zhao Y, O'Brien SM, Ferguson TB Jr, Peterson ED, Gammie JS, Song HK: Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010; 304:1568-75
9. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wong PY, Beattie WS: Influence of erythrocyte transfusion on the risk of acute kidney injury after cardiac surgery differs in anemic and nonanemic patients. ANESTHESIOLOGY 2011; 115:523-30
10. D'Ambra MN, Gray RJ, Hillman R, Jones JW, Kim HC, Rawitscher R, Schnaper H, Szymanski I, Vlahakes GJ, Kaplan D, Lynch KE, Guilfoyle M, Abels RI: Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64:1686-93 (Pubitemid 28066539)
11. Emmert MY, Salzberg SP, Theusinger OM, Felix C, Plass A, Hoerstrup SP, Falk V, Gruenenfelder J: How good patient blood management leads to excellent outcomes in Jehovah's witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011; 12:183-8
12. Weltert L, D'Alessandro S, Nardella S, Girola F, Bellisario A, Maselli D, De Paulis R: Preoperative very short-term, highdose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: A randomized blind controlled study. J Thorac Cardiovasc Surg 2010; 139: 621-6
13. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL: Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. ANESTHESIOLOGY 2011; 115: 929-37